Annual general shareholders ’ meeting of curasan AG fully supports plans of the management board

  • Annual general shareholde’s meeting approves all proposals of the executive management on the agenda
  • Stronger focus on orthopedics in the future
  • New image campaign presented
  • Corporate website now has new distributor area for easy access to extensive range of marketing materials

Kleinostheim, 23 June 2016 – The management board of curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, provided details of the current and future strategy of the company during the annual general shareholders’ meeting today, and responded to the questions of the shareholders in attendance. The annual general meeting approved all of the proposals of the management board in the agenda items that were put to the vote.

Michael Schlenk, CEO of curasan AG, explained to the about 100 shareholders present (30.5% of the voting shares) how the company will implement the more intensive focus of marketing, sales and distribution on the orthopedics sector in the future. He also offered insights into the recently announced strategies for expanding in the American and Chinese markets. “We earn two thirds of our revenues in the dental sector and one third in the orthopedics sector. However, the market overall has precisely the opposite ratio, with two thirds accounted for by orthopedics,” explained Schenk. “In the future we will increasingly focus on the largest market, namely orthopedics, but at the same time we will stay on top of the dental market as well.”

Schlenk also presented curasan’s new image campaign to the annual general meeting. As of today, the corresponding image film is available for downloading on the company’s website and will be made available on the familiar video portals together with additional video material in conjunction with the rollout in the next few months. “Our company was founded twenty-eight years ago. Our wholly synthetic range of CERASORB products is still state-of-the-art and its attractiveness even steadily increases against the background of surgical methods,” noted CEO Schlenk. “It is therefore important that we employ a contemporary approach to make the indisputable advantages of our products over competing products of animal origin or bone removed from patients’ own bodies clear to physicians and clinics.  Once they have recognized the benefits of CERASORB, they won’t want to use anything else.”

In order to provide improved support to its sales partners, curasan recently set up a separate distributor area on its recently re-designed corporate website, where newly created marketing materials are made available to the 70 distribution partners in more than 40 countries around the world and local sales efforts are supported by the company’s own teaching videos and background information prepared in-house. “Our products are very advanced, to be sure, but their application requires explanation. If we expect our distribution partners to generate sales and enjoy success in the market, we need to specify global strategies, adapt these to local conditions and provide intensive training and support to our partners around the world. curasan simply failed to do this in the past!” Schlenk stated emphatically.

Following the presentation of the annual financial report and the consolidated balance sheet for 2015, a clear majority of the shareholders present fully supported the current and future course of the company as shown by the approval of the agenda items put to the vote. Specifically, agenda items 2 through 6 were approved with the following percentages of voting shares:

Agenda Item 2:    99.94%
Agenda Item 3:    99.92%
Agenda Item 4:    99.98%
Agenda Item 5:    97.86%
Agenda Item 6:    99.10%

Further details of the agenda items put to the vote as well as the presentation of the annual general shareholders’ meeting held today are available for download on the website of curasan AG at https://www.curasan.de/en/investors/shareholders-meetingshare/

Your contacts at curasan AG:

Ingo Middelmenne
Head of Investor Relations
+49 6027 40 900-45
+49 174 90 911 90
ingo.middelmenne@curasan.com

Andrea Weidner
Head of Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

About curasan AG:
curasan AG develops manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting materials for dental and orthopedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopedics, traumatologists and spinal column surgeons worldwide benefit from the broad range of the premium quality and user-oriented portfolio offered by the technology leader. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park, near Raleigh, N.C., USA. The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange.